A number of cytokines modulate self-renewal and differentiation of hematopoietic elements. Among these is transforming growth factor ␤1 (TGF-␤1), which regulates cell cycle and differentiation of hematopoietic cells, but has pleiotropic activities depending on the state of responsiveness of the target cells. It has been previously shown by us and other authors that TGF-␤1 maintains human CD34
Introduction
Expression of the CD34 glycoprotein defines most immature progenitors and repopulating stem cells of the hematopoietic system. 1 A population of very primitive stem cells was recently found to be CD34 − , to have in vivo repopulating capacity after xenogenic transplants in immunodeficient mice, 2 and to become CD34
+ following exposure to differentiating stimuli. 3 The functions of CD34 are still largely unknown, but its structure is suggestive of a role as an adhesion molecule, 1 and recent data have shown that ectopic expression of human CD34 in murine cells does not effect development, but increases cellular adhesion. 4 CD34 expression is modulated during differentiation, and hematopoietic precursors gradually lose CD34 positivity when entering any specific differentiation lineage. 1 Moreover, forced expression of CD34 has been shown to block differentiation of murine leukemic cells. 5 Regulation of CD34 expression has been described at both transcriptional and post-transcriptional levels. Transcription factors such as c-myb, GATA-1, Ets, MZF and NFY have been described as possible regulators of the CD34 promoter in a number of cell lines. 1, 6, 7 Post-transcriptional mechanisms of CD34 regulation include stabilization of its specific mRNA with increased longevity 8 and hyperphosphorylation by activated protein kinase C, which can induce an increase in surface expression of CD34. 9 In this general context, the identification of factors that contribute to CD34 regulation is a key element for a better understanding of the biological processes underlying the complex functions of hematopoietic stem/progenitor cells. Various autocrine and paracrine soluble factors modulate the behavior and differentiation potential of hematopoietic elements, and may be involved in CD34 regulation. Among these factors is transforming growth factor-␤1 (TGF-␤1), which belongs to a family of molecules that exert pleiotropic effects on cells from various tissues. The functions of TGF-␤1 are tissue-and stage-specific, and include positive or negative effects on proliferation, differentiation, cell death and modulation of expression of adhesion molecules. [10] [11] [12] TGF-␤ receptors are serine/threonine kinases which mediate activation of a number of downstream effectors and kinase pathways, 13, 14 thus determining specificity of response in any particular system. 15 Signal transduction studies can hardly be performed on primary human cells, since the necessity for multiple isolation steps to select progenitors from the CD34 cell pool greatly reduces cell availability. Moreover, a great variability of response to various stimuli has been encountered in primary progenitor cells isolated from different individuals. A number of hematopoietic cell lines are available, which present various degrees of commitment, and offer suitable models to study hematopoietic differentiation. TGF-␤1 has been shown to decrease proliferation and induce differentiation of some of these cell lines. [16] [17] [18] Among these models, the erythroleukemia cell line TF-1 is of particular interest since it closely resembles hematopoietic progenitors, by expressing the CD34 antigen, being able to differentiate along different lineages upon treatment with differentiating agents, 19, 20 carrying TGF-␤ receptors 21 and producing endogenous TGF-␤1. 22 We have previously reported that endogenously produced TGF-␤1 is important in the maintenance of human CD34 + hematopoietic progenitors in an early, undifferentiated state, independently of any effects on the cell cycle. 23 In addition, recent work by Batard et al 24 has shown that TGF-␤1 contributes to the maintenance of CD34 expression in cord blood CD34 + cells. In the present work, we demonstrate that TGF-␤1 upregulates CD34 in the CD34 + hematopoietic cell lines TF-1 and KG-1a with a mechanism that is independent of cell cycle regulation. We show that this mechanism is due to transcriptional activation of CD34 in TF-1 cells. This effect of TGF-␤1 is associated with prevention of differentiation induced by 12-o-tetradecanoylphorbol-13-acetate (TPA) or by erythropoietin (EPO). These effects are mediated by activation of the receptor-activated Smad-2, and inhibition of p38 phosphoryl-TGF-␤1 activates CD34 and prevents differentiation of TF-1 cells M Marone et al 95 ation, which is independent of TGF-␤-activated kinase 1 (TAK1) induction.
Materials and methods

Culture of human hematopoietic cell lines
KG-1a, HL-60, K562 and TF-1 human hematopoietic cell lines were commercially purchased. KG-1a and HL-60 cells were maintained in IMDM with 20% fetal bovine serum (FBS) in T-25 flasks. K562 was maintained in IMDM with 10% FBS in T-25 flasks. TF-1 cells were maintained in RPMI with 10% FBS and 5 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF; Schering Plough, Milan, Italy) in T-75 flasks. Cultures in the presence or absence of anti-TGF-␤1 neutralizing mAb (R&D Systems, Minneapolis, MN, USA) (or equal doses of an irrelevant isotype-matched mAb as control) or human recombinant TGF-␤1 (R&D Systems) were carried out at 37°C, 5% CO 2 /95% air, in 24-well plates, with 25% Bit H9500 serum substitute (Stem Cell Technologies, Vancouver, Canada) and seeding a starting cell number of 1-2 × 10 5 cell/ml. TGF-␤1 was used in a concentration range of 1-20 ng/ml, usually at 5 ng/ml, except where otherwise specified. Anti-TGF-␤1 blocking antibodies were used in a concentration range of 10-50 g/ml, usually 20 g/ml, except when otherwise specified. To investigate transcriptional activation of CD34 RNA, TF-1 cultures were established in the presence of 5-10 g/ml actinomycin D (Sigma Chemical, St Louis, MO, USA) or its vehicle (Aceto-nitril) alone. To investigate TGF-␤1 effects on differentiation, macrophagic and erythroid progeny were obtained from TF-1 cells by culture for 120 h in serumfree conditions as described above, in the presence of 5 ng/ml GM-CSF and 200 ng/ml 12-o-tetradecanoylphorbol-13-acetate (TPA) (Sigma Chemical) or erythropoietin (EPO; 4 U/ml; R&D Systems).
In separate sets of experiments, TF-1 cells were cultured in serum-free conditions for 72 h in the absence of cytokines, in the presence of TGF-␤1 alone (5 ng/ml; R&D Systems) or in the presence of GM-CSF (5 ng/ml; Schering Plough), IL-3 (20 ng/ml; R&D Systems), interleukin-6 (IL-6; 5 ng/ml; R&D Systems), leukemia inhibiting factor (LIF; 500 IU/ml; R&D Systems), IL-6 superagonist K-7/D-6 (5 ng/ml; a gift of Dr G Ciliberto, IRBM P Angeletti, Italy), stem cell factor (SCF; 10 ng/ml; Amgen, Thousand Oaks, CA, USA) or Flt3 ligand (10 ng/ml; R&D Systems). To block p38 phosphorylation, the specific inhibitor SB202190 (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl) 1H-imidazole, from Calbiochem-Novachem, La Jolla, CA, USA) was added to the standard culture medium.
Flow cytometric studies
CD34 expression was measured by staining with a peridinin chlorophyll protein (PerCP)-conjugated anti-CD34 mAb (8G12; Becton Dickinson, San José, CA, USA) or phycoerythrin-conjugated (PE) anti-CD34 mAb (QBEND/10, Serotec; IMMU133, Coulter, Miami, FL, USA) followed by single-color or dual-color analysis on a FACScan flow cytometer (Becton Dickinson). Dual-color analysis was performed when CD34 staining was associated with tracking of cell division number by green fluorescence halving of carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) by flow cytometry and Modfit software, as described earlier. 23 Back- 26 Two l of these cDNA products were amplified with 1 unit of Ampli Taq Gold (PE Biosystems) in the presence of the specific primers for the mRNA of interest, together with the aldolase-A primers, 27 used as an internal control. Reactions were carried out in the Gene Amp PCR system 9600 (PE Biosystems). A first cycle of 10 min at 95°C, 45 s at 65°C and 1 min at 72°C, was followed by 45 s at 95°C, 45 s at 65°C and 1 min at 72°C for a number of cycles determined previously for each primer set. Conditions were chosen so that none of the amplification products obtained from the RNAs of interest reached a plateau and that the two primer sets did not compete with each other. Twenty-eight cycles were used for CD34 and lysozyme, 30 for bcl-2, and 26 for ␣-globin. The reactions for CD34, Bcl-2 and lysozyme were carried out in the presence of 1 mm MgCl 2 , those for ␣-globin in 3 mm MgCl 2 . The PCR products were loaded on to 2% agarose gels and stained with ethidium bromide. Each set of reactions included a no sample negative control. The ratio between the sample RNA to be determined and aldolase-A was calculated to normalize for initial variations in sample concentration and as a control for reaction efficiency. The sequences of the specific primers for aldolase A (primers A25 and H20), 28 bcl-2, 29 Bcl-x 30 and CD34 31 were described earlier. The following other primers were used for PCR: lysozyme, 5Ј-GCC AAATGGGAGAGTGGTTA-3Ј and 5Ј-ATCACGGACAACCC TCTTTG-3Ј; and ␣-globin, 5Ј-CAAGACCTACTTCCC GGCAACT-3Ј and 5Ј-AGAAGCCAGGAACTTGTCCA-3Ј. All oligonucleotide primers were synthesized by Pharmacia Biotech (Uppsala, Sweden).
Preparation of the cell lysates
Cell pellets were lysed in 20 mm Tris-HCl pH 7.4, 0.1 m NaCl, 5 mm MgCl 2 , 1% NP-40, 0.5% sodium deoxycholate, 50 mm NaF, 2 mm sodium vanadate (Na 3 VO 4 ), 1 mm PMSF, 2 g/ml leupeptin, 2 kallikrein inhibitor units/ml aprotinin for Western blotting. To separate the cytosolic and the nuclear fractions, cell pellets were resuspended in hypotonic buffer (5 mm TrisHCl pH 7.4, 5 mm KCl, 1.5 mm MgCl 2 , 0.1 mm EGTA pH 8, 0.2% Triton X-100, 1 mm DTT, 0.2 mm PMSF, 5 g/ml aprotinin, 5 g/ml leupeptin, 0.7 g/ml pepstatin A, 50 mm NaF). Nuclei were isolated from the cytosolic component by sedimentation at 500 g. After a wash in hypotonic buffer, the nuclear pellet was resuspended in Triton lysis buffer (150 mm NaCl, 10 mm Tris-HCl pH 7.4, 5 mm EDTA, 1% Triton X-100, 1 mm PMSF, 5 g/ml aprotinin, 5 g/ml leupeptin, 50 mm NaF, 2 mm Na 3 VO 4 ). Aprotinin, leupeptin and pepstatin were all purchased from Roche Diagnostics (Indianapolis, IN, USA), all other reagents from Sigma.
Western blot analysis and antibodies
The protein concentration was determined using the BioRad Protein Assay (BioRad Laboratories, Hercules, CA, USA). 150 g of each protein sample was used for CD34 detection, whereas for Smad-2 and p38, 70 g of the cytosolic and 35 g of the nuclear fractions were used. Samples were separated by SDS-PAGE and electroblotted on polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). Membranes were then incubated with 6% non-fat dry milk in 1 × TBST (0.1 m Trizma Base, 0.15 m NaCl, 0.05% Tween 20, pH 7.4) for blocking, and then with the specific primary antibodies in 3% non-fat dry milk, 1 × TBST. Following incubation with the appropriate secondary antibody (horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse, BioRad), p38 and CD34 detection was performed with the ECL-Plus system (Amersham International, Amersham, UK) and exposure to X-AR-5 OMAT Kodak films (Kodak, Rochester, NY, USA). For Smad-2 and ␤-actin, visualization of the bound antibody was performed with the 5-bromo-4-chloro-3-indolyl-phosphate/nitroblue tetrazolium (BCIP/NBT) phosphatase substrate system (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA). A control Western blot with ␤-actin was performed on all samples to confirm equal loading. The following antibodies were used for Western blotting: mouse monoclonal anti-Smad-2 (Transduction Laboratories, Lexington, KY, USA), anti-CD34 QBEND10 (Coulter), anti-␤-actin, clone AC-15 (Sigma), anti-TAK-1 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), and rabbit polyclonal anti-phosphop38 (Cell Signaling, Beverly, MA, USA).
Image analysis and quantification
Images of the RT-PCR ethidium bromide-stained agarose gels, X-ray films and alkaline phosphatase-stained PVDF membranes, were acquired with a Cohu CCD camera and quantification of the bands was performed by Phoretix 1 D (Phoretix International, Newcastle upon Tyne, UK). Band intensity was expressed as relative absorbance units. Comparisons between the distinct parameters evaluated in study and control cultures were made by two-tailed Student's t-test. A P value Ͻ0.05 was considered significant. The mean and standard deviation values given in the text or in the figures are obtained from at least three independent experiments.
Results
TGF-␤1 induces CD34 expression in hematopoietic cell lines
Addition of exogenous TGF-␤1 (5 ng/ml) in medium containing a serum substitute (see Materials and methods) to the CD34 + TF-1 cell line produced a drastic increase in CD34 expression clearly visible by flow cytometry after 72 h with a shift in the median fluorescence channel from 15 to 94 (mean of three independent experiments: 15 ± 3 and 94 ± 7), whereas depletion of endogenously produced TGF-␤1 by specific anti-TGF-␤1 neutralizing antibodies (10 g/ml) had no significant effect ( Figure 1a ). We investigated this phenomenon in a few other cell lines to determine specificity of response to TGF-␤1 in terms of CD34 expression. Addition of TGF-␤1 to the CD34 + KG-1a cell line at the same concentration and for the same length of time as those used for TF-1 cells produced a significant increase in CD34 protein expression (shift in median fluorescence channel from 451 to 758, mean of three independent experiments: 448 ± 17 and 760 ± 37), whereas no effect was observed following neutralization of endogenous TGF-␤1 (Figure 1b) . Conversely, the CD34 − K562 and HL-60 cell lines did not acquire the CD34 protein when exposed to exogenous TGF-␤1 (Figure 1b) . No significant change in total cell number was observed in any of these cell lines when exogenous TGF-␤1 was added at 5 ng/ml for up to 72 h (data not shown, see below for TF-1 cells). Moreover, evaluation of CD34 expression and cell division number by CFDA-SE showed that the rate of cell division in TF-1 cells was not affected by 5 ng/ml TGF-␤1, and that upregulation of CD34 occurred both in divided and in undivided cell populations (Figure 2a) . Analysis of the forward scatter vs CD34 expression did not change in control, TGF-␤1-or anti-TGF-␤1-treated TF-1 cells (median forward scatter channel = 540 in all three conditions, Figure 2b ).
TF-1 cells are routinely grown in the presence of GM-CSF, but a variety of hematopoietic growth factors including IL-3, IL-6, LIF, and SCF are capable of supporting their growth and survival. The ability of these cytokines, of IL-6 superagonist K7/D-6 and of Flt3 ligand to modulate the CD34 protein was tested alone and in combination with TGF-␤1. After 72 h of culture in the presence of each of these cytokines, TF-1 cells showed an approximately five-fold increase in cell number, which was comparable to the increase obtained in standard culture conditions with GM-CSF (Figure 2c, upper panel) . Addition of TGF-␤1 at 5 ng/ml did not significantly affect cell growth in any of the combinations tested except with K7/D-6, where a modest growth inhibition effect was observed. TGF-␤1 alone did not cause any significant growth arrest, while producing a five-fold increase in CD34 expression level.
In the absence of TGF-␤1, none of the cultures showed any significant change in CD34 expression, whereas all cytokines in combination with TGF-␤1 produced a considerable and significant increase in the mean fluorescence channel (fourto five-fold) after staining with anti-CD34 mAb as compared to the respective controls without TGF-␤1 (Figure 2c , lower panel).
Flow cytometric localization of CD34 protein and Western blot analysis in TF-1 cells
Dual-color staining with PE anti-CD34 mAb, cell fixation and subsequent permeabilization and restaining with FITC anti-CD34 mAb allowed separate identification of membrane and cytosolic CD34. We were thus able to demonstrate that, following TGF-␤1 treatment for 72 h in serum-free medium, CD34 protein levels in TF-1 cells increased both on the membrane and in the cytosol (Figure 3a and b) . In particular, a mean 3.5-fold ± 0.53 increase in mean fluorescence was detected on the membrane and a mean 1.5-fold ± 0.32 increase in the cytosol. Additional flow cytometric analyses showed that induction of CD34 expression by TGF-␤1 was detected by classes of anti-CD34 monoclonal antibodies (QBEND10 for class II and IMMU 133 for class I) other than the routinely used class III 8G12 (data not shown). Induction of the CD34 protein by TGF-␤1 in TF-1 cells was confirmed by Western blot analysis, using the QBEND10 antiLeukemia body (Figure 3c) . A band was barely visible in the untreated control, whereas a dramatic increase, confirmed in three independent experiments (mean 19 ± 4.5-fold), was seen in TGF-␤1-treated TF-1 cells. ␤-Actin was used as a positive control to confirm equal loading between the TF-1 lanes. The strongly CD34 expressing cell line KG-1a was used as a positive control. The band corresponded to the expected molecular weight of 115-120 kDa.
Modulation of CD34 RNA levels by TGF-␤1
Semiquantitative RT-PCR analysis of CD34 RNA in TF-1 cells showed that TGF-␤1 caused a dramatic increase in CD34 RNA levels (Figure 4a ). The primers (5) were selected so that only the functional, full-length form of CD34 RNA could be detected. 31 A concentration of TGF-␤1 of 5 ng/ml was sufficient to induce maximal increase in RNA levels (Ͼeight-fold). Depletion of endogenous TGF-␤1 by use of neutralizing mAb caused a four-fold decrease of the CD34-specific RNA product at both concentrations tested (10 and 20 g/ml). A comparable TGF-␤1-induced activation of CD34 RNA was observed when the TF-1 cell line was cultured with IL-3 instead of GM-CSF (Figure 4a, lanes 6 and 7) . The RNA levels of the survival proteins bcl-2 and bcl-x L , and the transcription factor c-myb, one of the known regulators of CD34 expression, did not change significantly (Figure 4a ). The differentiation markers ␣-globin and lysozyme showed no relevant change (data not shown). A time-course analysis showed that the transcriptional increase was already visible at 16 h, reached a plateau at 48 h and then declined in longer treatments (Figure 4b ). c-myb RNA level did not change during this treatment and was only mildly dowmodulated by anti-TGF-␤1 at 72 h, as was to be expected in differentiating cells (Figure 4b) . To rule out possible post-transcriptional mechanisms of RNA modulation, 32 we induced a block in RNA synthesis by adding actinomycin D together with TGF-␤1 in the culture medium. Actinomycin D completely inhibited TGF-␤1-induced overexpression of CD34 RNA, proving that the increase in RNA levels was due to ex novo CD34 RNA synthesis (Figure 4c ).
Effects of TGF-␤1 on cell cycle and differentiation of TF-1 cells
We have previously shown in primary hematopoietic precursors that autocrine or exogenous TGF-␤1 exerts both antiproliferative and anti-differentiating effects.
23,24 TF-1 cells cultured for 72 h with different doses of exogenous TGF-␤1, showed no significant perturbation of cell cycle phases up to 5 ng/ml, as shown by bromodeoxyuridine (BrdUrd) incorporation, propidium iodide (PI) staining and flow cytometric analysis. Conversely, concentrations of exogenous TGF-␤1 of 10 ng/ml or higher produced a dose-related reduction in the number of cells in the proliferative compartments of the cell cycle. In particular, the percentage of cells in S phase declined, on average, to 30% of control with 10 ng/ml of TGF-␤1 and to 25% with 20 ng/ml TGF-␤1. At both doses of TGF-␤1, cells accumulated in the G1 phase. Control cultures yielded an average S-phase value of 49% (P Ͻ 0.012 and P Ͻ 0.009, respectively, see Table 1 ). Doses of anti-TGF-␤1 lower than 30 g/ml did not cause any significant perturbation of cell cycle phases, while 40-50 g/ml of anti-TGF-␤1 gave a 15-25% increase in the number of cells in the S-phase and a 10-15% decrease in cells in the G1-phase.
Treatment with TPA induces a pronounced differentiation of TF-1 cells into macrophage-like cells, whereas EPO sustains the short-term growth of these cells and induces their differentiation along the erythroid lineage. 19 When TF-1 cells were induced to differentiate in the presence of 5 ng/ml TGF-␤1, a consistent reduction of the frequency and absolute number of + KG-1a cell line used as a control. The 111 kDa band of the molecular weight standards is indicated. ␤-Actin was used as a control on the same blot, to confirm equal loading in the two TF-1 cell samples. The lower panel is the diagram obtained from the mean and standard deviation of three independent experiments, one of which is shown above.
Figure 4
Semi-quantitative RT-PCR analysis for CD34: ethidium bromide-stained agarose gels. The lower band in all panels is aldolase-A, which was used as an internal control. C (GM-CSF) 9 ± 2 5 1 ± 5 1 5 ± 3 2 5 ± 4 4 9 ± 7 +TGF-␤1 1 ng/ml 11 ± 3 5 3 ± 8 1 4 ± 4 2 2 ± 3 5 1 ± 10 0.219 +TGF-␤1 5 ng/ml 14 ±4 5 3 ± 11 10 ± 2 2 3 ± 5 5 0 ± 9 0.210 +TGF-␤1 10 ng/ml 12 ± 3 6 6 ± 5 1 2 ± 3 1 0 ± 4 3 0 ± 6 0.012 +TGF-␤1 20 ng/ml 9 ± 4 7 5 ± 7 7 ± 3 9 ± 5 2 5 ± 6 0.009 differentiating progeny was measured in cultures leading to both macrophagic and erythroid differentiation ( Table 2) . Reduction in the frequency of phenotypically defined nascent erythroid and macrophagic cells due to TGF-␤1 averaged 50 and 80%, respectively. The addition of TGF-␤1 to differentiating TF-1 cells did not cause any significant growth arrest. Anti-TGF-␤1 at 20 g/ml produced a consistent increase in the frequency of differentiating cells (15-25% for erythroid and 15-30% for macrophagic cultures), but not in their absolute number (data not shown).
Modulation of CD34 and bcl-2 RNA levels by TGF-␤1 during induced differentiation of TF-1 cells
We selected lysozyme and ␣-globin as molecular markers to monitor TPA-and EPO-induced differentiation of TF-1 cells after 5 days of treatment and at the same time we evaluated CD34 and bcl-2 RNA levels by semiquantitative RT-PCR. Treatment with TPA alone caused no change in CD34 expression, a 3.2-fold decrease in bcl-2, and a dramatic decrease in ␣-globin. Alpha-globin is normally expressed at very high levels in untreated TF-1 cells and its decrease is indicative of a switch towards a macrophage-, rather than erythroid-like phenotype. Moreover, we measured a two-fold increase in lysozyme expression compared to control ( Figure  5a and b) , as was to be expected for a marker of differentiation into the macrophage lineage. When TGF-␤1 was added together with TPA, we detected a 6.7-fold increase in CD34 RNA levels. Bcl-2 on the other hand, increased by 4.2-fold Table 2 Surface marker expression on TF-1 cells exposed to differentiating factors leading to macrophagic (GM-CSF + TPA) or erythroid (EPO) differentiation in the presence or the absence of exogenous TGF-␤1 Count CD64
A starting number of 1 × 10 5 TF-1 cells were cultured in serum-free conditions for 5 days in the presence of various factors and then counted and analyzed by flow cytometry. Results are expressed as the mean ± s.d. observed in five independent experiments. NE, not evaluated. a P Ͻ 0.001 as compared to GM-CSF + TPA. b P Ͻ 0.003 as compared to EPO.
(compared to the TPA control), and was thus maintained in a similar way to the untreated control. Alpha-globin increased by 1.6-fold and lysozyme decreased by three-fold as compared to TPA control, indicating a partial block of induced macrophagic differentiation. Anti-TGF-␤1 in combination with TPA caused a dramatic decrease in bcl-2 expression (2.7-fold) and a decrease in ␣-globin (1.5-fold) compared to the TPA control indicating an enhancement of induction of the differentiated phenotype.
EPO alone induced an increase in CD34 expression (2.3-fold), a mild decrease in bcl-2 (1.5-fold) and a strong increase in ␣-globin (2.4-fold; Figure 5a and b) confirming differentiation towards the erythroid lineage. When TGF-␤1 was included together with EPO, CD34 expression increased by 4.3-fold, an indication that EPO-induced differentiating effects were inhibited, ␣-globin decreased slightly, also indicating a partial reversion of phenotype, whereas none of the other parameters was significantly affected. On the other hand, anti-TGF-␤1 caused a 1.4-fold decrease in bcl-2 levels and 1.3-fold in CD34, but did not cause any other significant change compared to the EPO control.
Signal transduction pathways modulated by TGF-␤1 in TF-1 cells
TGF-␤1 is known to transduce its signal through a specific receptor system and a number of downstream effectors. Among these are the Smad proteins, which following induction, are translocated to the nucleus where, alone and in com- bination with a number of transcription factors they modulate transcription. To determine specificity of the signaling activated by TGF-␤1 in TF-1 cells, we looked at Smad-2 translocation. Western blot analysis of cytosolic and nuclear fractions of control and TGF-␤1-treated TF-1 cells showed a three-fold increase in nuclear Smad-2 in treated vs control cells, after normalization to the ␤-actin control (Figure 6a ). Treatment for 90 min to 2 h showed that induction was maximal at 1 h (data not shown).
TGF-␤1 can also transduce its signal through a TGF-␤-activated kinase (TAK1), which is upstream of the MAP kinase pathways. The specific pathways involved are strictly dependent on the system, although activation of JNK and p38 are commonly described, sometimes accompanied by ERK activation. [33] [34] [35] [36] We looked at ERK1 and 2, JNK and p38 by Western blotting using antibodies specific for the activated, phosphorylated forms of these kinases. Following TGF-␤1 treatment for 1 h, we observed no significant change in phospho-Erk levels, but a slight increase in phospho-JNK (Figure  6b) , an effect, which has been described before. 36 Unexpectedly, we also observed a drastic decrease in p38 phosphorylation (Figure 6b ). This decrease was confirmed in separate experiments at longer time-points and was maximal at 1 h (6.5-fold decrease, after normalization to ␤-actin), but persisted up to 48 h. In the same experimental conditions, we observed an increase in TAK-1 protein level by two-fold upon a 1 h treatment (Figure 6a ), increase which persisted up to 48 h (data not shown).
A number of factors have been described as possible modulators of the CD34 promoter, including GATA-1 and c-myb, whose activity can be modulated at a transcriptional level. 37, 38 However, treatment with TGF-␤1 for 16 to 72 h caused no significant change in c-myb at RNA (Figure 4) or protein levels Leukemia (data not shown). In agreement with our previous studies on human CD34
+
/CD105
+ proliferating progenitors, 23 in TF-1 cells anti-TGF-␤1 increased GATA-1 levels (1.45-fold), as was to be expected in differentiating cells, whereas TGF-␤1 only slightly decreased GATA-1 levels (0.74-fold). No significant change was observed in the Ets-family member PU.1 upon TGF-␤1 treatment (data not shown).
In order to determine the relevance of p-38 modulation of CD34 trancription, we tested the effects of the specific inhibitor of p-38 phosphorylation SB 202190, which has no effects on the activity of the ERK and JNK MAP kinase subgroups. When TF-1 cells were exposed to 0.5 m SB202190 for 48 h, no detectable effects were seen on cell growth, but a consistent increase in CD34 transcription was detected (increase in CD34 expression: 2.85 ± 0.23, mean of three independent experiments, Figure 6c ).
Discussion
The mechanisms that regulate the maintenance of the human hematopoietic stem/progenitor pool are still poorly understood, but it is well known that multipotent blood-cell forming progenitors express the CD34 antigen and gradually lose it as they become more committed. 1 These multipotent progenitors are likely to originate from long-living stem cells which are believed to lack CD34 expression. [1] [2] [3] 39 Hence, CD34 is a key molecule in hematopoietic differentiation and it is clearly of utmost importance to determine the factors that regulate its expression developmentally. TGF-␤1 is an anti-differentiating soluble molecule that can counteract the differentiating effects of most of the known hematopoietic cytokines that modulate cell cycle and differentiation. 10 We have previously shown that depletion of endogenously produced TGF-␤1 can trigger differentiation of CD34 + progenitors in the absence of any significant effects on the cell cycle profile. 23 Moreover, Batard et al 24 have recently shown that TGF-␤1 is important in the maintenance of CD34 expression in CD34
+ cord blood cells in culture. Previous studies have demonstrated that TFG-␤1 blocks proliferation and induces differentiation of many myeloid and leukemia cell lines, including TF-1, KG-1a, HL-60, K-562 in serum-containing cultures. 16, 40 Our study shows that TGF-␤1 at 5 ng/ml induces CD34 expression in the CD34 + cell lines TF-1 and KG-1a independently of any cell cycle effects when the cells are cultured with a serum substitute. This induction of CD34 was striking (Ͼfive-fold) mostly in TF-1 cells. In KG-1a cells, which already express CD34 at extremely high and probably close to saturation levels, the induction, although significant, was reduced as compared to TF-1 cells. TGF-␤1 had no effect on CD34 expression in the CD34 − cell lines HL-60 and K-562. We hypothesize that TGF-␤1 can act as an inducer of CD34 expression only in responsive cells, ie cells in early phases of hematopoietic development and that once differentiation has progressed downstream of the CD34 + stage (ie HL-60 and K-562 cell lines), TGF-␤1 is unable to activate transcription of the CD34 gene. Differentiation would cause permanent loss of some factor/s essential for CD34 transcription or otherwise the gain of some factor/s which would block CD34 transcription irreversibly. Moreover, TF-1 cells represent an earlier developmental stage than KG-1a since they are endowed with multipotent capacities when exposed to the appropriate stimuli, 41, 42 whereas KG-1a are more committed to the myeloid lineage. 43 Previous data have shown that TGF-␤1 can exert opposite effects in very primitive CD34
++
CD38
− and in CD34 + CD38 + human hematopoietic progenitors. 44 CD34 could be one of the key molecules that are involved in this response. In an early progenitor stage (such as CD34 + cells) CD34 could be directly or indirectly responsible for the anti-differentiating effect of TGF-␤1, which also acts as a potent upmodulator of bcl-2, a wellknown survival factor for these cells. 23 In later stages (CD34 − cells), response to TGF-␤1 can be either pro-or antidifferentiation in specific differentiation steps of the various hematopoietic lineages and is therefore independent of CD34 expression. 10 Interestingly, the effect of TGF-␤1 on CD34 expression was independent of the cytokine used for the maintenance of TF-1 cells in culture. Moreover, none of the cytokines tested was able to induce CD34 expression, nor to counteract TGF-␤1-induction of CD34, demonstrating a distinct specificity of TGF-␤1 in activating CD34. We show that this increase in CD34 expression, evident as increased protein levels both in the cytosol and on the membrane is due to a striking transcriptional upregulation, as shown by using actinomycin D, which completely abolished TGF-␤1-induced transcription of CD34. CD34 mRNA level was maximally induced by eight-fold, whereas its protein level was shown to increase by five-to 19-fold depending on the technique used (flow cytometry or Western blotting) and on the antibodies used (which are specific for different types of glycosylation products). Previous studies have shown that membrane proteins, such as CD34, have a half-life that is much longer than that of their corresponding mRNAs. 45 Indeed only a portion of the CD34 antigen-positive cells was found to contain CD34 RNA. 46 RT-PCR was performed so that the 3Ј primer recognized the 3Ј sequence of CD34 that is present only in the full-length mRNA, to ensure that only the functional form would be detected. 5 Our data, which suggest that defective expansion and/or maintenance of the progenitor cell compartment would occur in the absence of TGF-␤1, is in agreement with the observation that TGF-␤1-knockout mice bear severe hematopoietic defects due to massive reduction of the blood cell pool and defective formation of blood vessels. 47 A number of transcription factors has been described as modulators of CD34 in vitro. 1, 6, 7 Among these, is GATA-1 that appeared to be only mildly negatively modulated by TGF-␤1 in TF-1 cells. This observation indicates that GATA-1 is probably only marginally involved in the response to TGF-␤1. Possibly, it may be involved only indirectly as a consequence of the anti-differentiative response. The CD34 promoter contains multiple c-myb binding sites and overexpression of cmyb has been described as responsible for CD34 increased transcription in vitro. 48, 49 Our data, which showed no modulation of c-myb in association with CD34 upregulation, are in support of the observations that c-myb, although necessary for definitive hematopoiesis, is not required for CD34 expression in primitive hematopoietic cells. 50 Moreover, downregulation of c-myb by TGF-␤1 has been described only in systems whose differentiation is induced by the latter, 51, 52 indicating that the signaling involved is strictly specific. This specificity may determine the diversity of response in cell types in different developmental stages.
A number of other early effectors downstream of TGF-␤1 receptor activation appear to act prior to CD34 upmodulation. Various studies have demonstrated that TGF-␤1 signaling activates two independent pathways, one mediated by the Smad family of proteins and the other by TAK1. 13, 14 In the Smad pathway, TGF-␤1 stimulation is mediated by Smad-2 and leads to activation of transcription of a number of specific genes. [53] [54] [55] TAK1 is a member of the MAPKKK family (mitogen-activated protein kinase kinase kinase) and among its known substrates are MKK3, MKK4 and MKK6, which in turn can activate p38 and JNK (stress-activated protein kinase/c-Jun N-terminal kinase). 56, 57 Independently of the MKK system, TAK-1 can also regulate different transcription factors. 54, 58, 59 In order to study specificity of response to TGF-␤1 in our system and to understand which mechanisms may mediate the final outcome on CD34 expression, we investigated the effects on the Smad and TAK1 signal transduction pathways. In our system, TGF-␤1 led to activation of Smad-2 and hence to its translocation to the nucleus. It is well known that activated Smad-2 can interact with a number of other Smads and transcription factors, which in turn activate or inactivate different genes and hence determine specificity of response. 15, 53, 54 The induction of CD34 we have observed as a common response in CD34
+ cell lines only, could be due to some effectors that are permanently lost upon differentiation, which prevent any further transcription of the CD34 gene. TAK-1 is normally activated by TGF-␤1, 36 as we have confirmed in TF-1 cells, where it could be responsible for the mild JNK induction we observed. TAK1 has been shown to be upstream of p38 and to be able to activate p38 during differentiation processess, 56, 59, 60 but other kinases are also upstream of modulation of MKK6 and p38 in differentiative processes in various tissues, 58, 59 P38 in particular and has been shown to be specifically activated during erythroid differentiation induced by EPO or IL-3. 61, 62 Moreover, a number of recent reports has shown that the p38 pathway is activated by TGF-␤1-induction of differentiation in a number of systems.
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In TF-1 cells, where TGF-␤1 acts by inducing CD34 expression, by activating Smad-2 and TAK1, and by preventing differentiation, we detected a marked downregulation of p38 phosphorylation. The response of TF-1 cells to TGF-␤1 is hence distinctly specific and different from the most common response described in other systems. The activation of TAK1 and the concomitant block of p38 phosporylation in TF-1 cells proves that p38 can be modulated independently of TAK1. The relevance of p38 in CD34 upregulation in our system was confirmed by using the specific inhibitor of p38 phosphorylation SB202190. This inhibitor, which is specific for p38 and does not affect Erk or Jnk, caused an upregulation of CD34 by 2.95-fold. The transcriptional increase of CD34 expression induced by TGF-␤1 was more striking (Ͼeight-fold), which can be explained both by the difficulty of inducing a complete block of p38 with the specific inhibitor in the absence of toxic or non-specific effects, and also by the fact that other mechanism may still be involved in TGF-␤1 signal transduction. This observation leads us to believe that although a more complex modulation may be present, p38 is certainly one player which can modulate CD34 expression. Our data, along with the reported p38 activation in other systems, allow us to hypothesize that p38 could be a common mediator of TGF-␤1-regulated differentiation. When p38 is activated, differentiation is induced, whereas when p38 is repressed, as in our system, differentiation is prevented. At present, we have no indication to determine whether this phenomenon is a direct consequence of TGF-␤1 treatment or is a secondary effect due to the modulation of differentiation.
The present findings demonstrate the effects of TGF-␤1 in preventing differentiation of hematopoietic multipotent cells and in the maintenance/induction of CD34 expression in the absence of any significant effect on cell proliferation. These events are associated with modulation of multiple pathways mediated by activation of Smad-2 and TAK1 and by inhibition of still undefined upstream kinases that block p38. We also demonstrated that these pathways are modulated independently of each other. The balance of these three (and possibly more) alternative pathways could determine the distinct differentiating responses to TGF-␤1 in TF-1 cells.
Studies are now in progress to expand these data to primary progenitor cells. Preliminary experiments demonstrated that TGF-␤1 has similar effects on human primary CD34 + cells, including induction of CD34 expression and p38 inactivation. Understanding these mechanisms of modulation of differentiation can contribute to a better comprehension of the biological processes that regulate the early stages of human hematopoiesis. Moreover, it can provide better tools to modulate the hematopoietic commitment and potential of human stem cells and improve their maintenance ex vivo.
